Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
AEG Osman, MW Deininger - Blood reviews, 2021 - Elsevier
… Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm … of Imatinib initially as
salvage therapy in 2001 and subsequently as front line therapy revolutionized CML therapy, …
salvage therapy in 2001 and subsequently as front line therapy revolutionized CML therapy, …
Chronic myeloid leukemia prognosis and therapy: criticisms and perspectives
D Russo, JV Garcia-Gutierrez, S Soverini… - Journal of Clinical …, 2020 - mdpi.com
… , S.; Iacobucci, I.; De Vivo, A.; Testoni, N.; Castagnetti, F.; Gugliotta, G.; et al. Effects and
outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid …
outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid …
[HTML][HTML] Chronic myeloid leukemia in 2020
R Hehlmann - Hemasphere, 2020 - journals.lww.com
… The first trial with imatinib, a phase I study with poor risk CML patients, started in 1998. The
stunning results convinced even skeptics that further studies were indicated. In 1999, a group …
stunning results convinced even skeptics that further studies were indicated. In 1999, a group …
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
V García-Gutiérrez, M Breccia, E Jabbour… - Journal of Hematology & …, 2022 - Springer
… Real-world evidence from low- and middle-income countries demonstrated that a decreased
adherence to imatinib treatment was associated with lower 10-year event-free survival [37]. …
adherence to imatinib treatment was associated with lower 10-year event-free survival [37]. …
Revisiting six established practices in the treatment of chronic myeloid leukaemia
HM Kantarjian, MA Welch, E Jabbour - The Lancet Haematology, 2023 - thelancet.com
… Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year
survival results of the randomized CML study IV and impact of non-CML determinants. …
survival results of the randomized CML study IV and impact of non-CML determinants. …
[HTML][HTML] Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?
S Branford - Haematologica, 2020 - ncbi.nlm.nih.gov
… Do we need to increase the sensitivity of detection of BCR-… identify the patients who would
likely remain in treatment-free … chronic myeloid leukemia (CML) were treated with imatinib in …
likely remain in treatment-free … chronic myeloid leukemia (CML) were treated with imatinib in …
Imatinib improved the overall survival of chronic myeloid leukemia patients in low-and middle-income countries: A therapeutic goal has been reached
M Breccia - EClinicalMedicine, 2020 - thelancet.com
… with chronic myeloid leukemia (CML) has drastically changed following the introduction of
different tyrosine kinase inhibitors (TKIs). In particular, long-term results obtained with imatinib, …
different tyrosine kinase inhibitors (TKIs). In particular, long-term results obtained with imatinib, …
… vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the …
JE Cortes, Q Jiang, J Wang, J Weng, H Zhu, X Liu… - Leukemia, 2020 - nature.com
… Not Have Favorable Response to Imatinib; NCT01593254) is the first and only prospective
… in patients with lack of EMR to first-line imatinib. Here we present the first results of this study, …
… in patients with lack of EMR to first-line imatinib. Here we present the first results of this study, …
Chronic myeloid leukemia: where do we stand, where can we go?
K Lewandowski… - Acta Haematologica …, 2022 - journals.viamedica.pl
… Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the
randomized BFORE trial. J Clin Oncol. 2018; 36(3): 231–237, doi: 10.1200/JCO.2017.74.7162, …
randomized BFORE trial. J Clin Oncol. 2018; 36(3): 231–237, doi: 10.1200/JCO.2017.74.7162, …
[PDF][PDF] Imatinib mesylate adherence in chronic myeloid leukemia patients: Data from middle euphrates region of Iraq
A Mjalia, SK Abbasb - Higher education, 2021 - researchgate.net
… In this study we try to assess adherence of CML patients to imatinib in Middle Euphrates
region of Iraq.This study can … Do you sometimes forget to take your medication? …
region of Iraq.This study can … Do you sometimes forget to take your medication? …